Trade Gilead Sciences Inc - GILD CFD

Gilead Company profile

What is Gilead Sciences?

Gilead Sciences Inc. is a US biopharmaceutical company. Following a series of mergers and acquisitions, Gilead is now one of the biggest players in its field with almost 9,000 employees working all over the globe. A portfolio of shipped products includes medicals for HIV treatment and HIV prevention. Gilead focuses on medical products that serve to cure oncology, liver diseases, cardiovascular disorders and many other severe health conditions. Gilead has a wide network of partnerships and collaborations.
 

What does the company do?

A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.

The portfolio of Gilead’s products and investigational drugs includes innovative treatments for AIDS/HIV, cancer, respiratory, inflammatory, liver diseases and cardiovascular conditions.
 

A bit of Gilead Sciences’ history

Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.

 

Who founded Gilead Sciences?

Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.

 

Establishing the company and its vision, Michael L. Riordan collaborated with three major scientific advisors, including Doug Melton of Harvard, Peter Dervan of Caltech and Harold Weintraub of the Fred Hutchinson Cancer Research Center.
 
A venture capital firm Menlo Ventures, where Riordan worked for one year, made the first investment of $2 million into Gilead Sciences.
 

Current size, team and locations

Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.

 

Quick facts about Gilead Sciences

  • Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
  • It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
  • In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
  • In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.

How to learn the Gilead Sciences share price?

Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the US Tech 100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.

Latest shares articles

Meme stocks make a comeback, but blue chips deliver better returns for traders
Equity trading in Tesla, Coinbase and Apple report highest share of profits; use of stop loss protection reveals better risk-adjusted profits over the summer months
13:23, 8 October 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
09:20, 29 August 2024
Lloyds share price forecast: An attractive dividend stock?
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
13:36, 8 July 2024
Exterior of Infosys headquarters
Infosys shareholders: Who owns the most INFY stock?
Who are the major shareholders and decision-makers of Infosys?
07:12, 29 April 2024

Read our reviews to find out more about us

Read the feedback from our clients around the world.

the simplicity and the pros of this app makes it amazing and a useful app

Hafsa

I have already tested many brokers and I can definitely say that Capital.com is the most professional trading tool.

PaCeKw

Capital.com is a good broker. I haven't had any problems with the trading platform but i qould advise that they add an option for either using lots or units.

Mr-phenom

I am in the first time but I look this website in YouTube there's a very good and safe platform for a traders Thinks for taking my opinion

MUHAMMAD JALIL MUHAMMAD ASGHAR

great UI, simple platform, low spreads, great coverage

Jihad Kattar

The videos are easy to follow, i get my profits and downs and understand the market now even more. This app is very well to understand. I would recommend this app to friends if they want to know.

Customer

Good and amazing app for trading and easy setups easy and smooth buy and sell amazing

QAISAR ALI

Excellent for people who would like to get and build all the experience needed to navigate to Stock Market.

Johnsy81

Overall my experience is very good with capital, the one best thing is they give you call support with most other broker apps don’t gives.

Ranjit

I have been usingCapital.comm platform for a year now. I did have some issues with using the platform in the earlier days but I received excellent support from Capital.com guiding me in the process of learning about the platform and put me on track. I am very happy with this platform and find it very easy to use for my trading needs. Capital.com also arranged a series of trading webinars last summer, which I attended and benefited from.

Dr Anjum Pervez

The best app for trade ever I tried to much trade app and this is the best

Moamen

Great website, easy to use and user friendly. Lot of markets to trade with. Good database of information and learning tutorials for beginner. Great customer support. I had some issues and they helped me solve them rapidly. One of the best broker, I recommend.

Nicolas Crampet

Trusted trading Platform Capital.com is the most trusted trading platform I ever experienced. Even without taking any demo,I have started funding and it’s going well. It is a very easy platform for the beginners and can have better trading experience by using this

JEYAKUMAR

great app, love the weekly and monthly insights, and review they send about my trading habits. spread for gold is usually 0.3 but at times fluctuates up to 0.9 this often makes it hard trading on the low time frames and not losing my position to spread even if my bias was correct, if the spread was better I'd give 5 star.

chris hoeben

Capital.com is the best broker of all time and I Should give it five stars but there is a small issue about execution of my orders through traddingview it is a bit slow. But the execution of orders directly from the capital.com App or Website is absolutely fast and apart from that everything is simple incredible.

IKOFO MOISE

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading